Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy
Top Cited Papers
- 1 March 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 5 (2), 241-248
- https://doi.org/10.1161/circheartfailure.111.963991
Abstract
Background—: The HeartMate II (HMII) destination therapy (DT) trial demonstrated significant improvements in outcomes in continuous-flow left ventricular assist devices compared with patients implanted with the pulsatile-flow HeartMate XVE. The primary hypothesis of the current study is that trial patients enrolled after the initial data cohort would have better clinical outcomes. Methods and Results—: Two hundred eighty-one patients who underwent HMII for DT from May 2007 to March 2009 (Mid Trial [MT] group) were compared with the initial 133 HMII patients from March 2005 to May 2007 (Early Trial [ET] group). Patient entry criteria were the same during the 2 time periods. Survival, adverse events, and quality of life were compared between the 2 groups. Baseline characteristics were similar between the groups. Compared with the ET group, patients in the MT group had reduced adverse event rates for bleeding requiring transfusions (1.66 versus 1.13 events per patient-year, P P =0.025), device-related infections (0.47 versus 0.27, P P =0.01). Other event rates were similar between groups including ischemic stroke (0.06 versus 0.05 events per patient-year, P =0.57). Survival at 1 year in the MT group was 73% versus 68% in the ET group ( P =0.21). Additionally, there was a significant reduction in deaths caused by hemorrhagic stroke ( P =0.01). Quality of life improvements were significant in both the groups ( P <0.001). Conclusions—: The benefit of DT therapy with the HMII is confirmed in subsequent trial patients, with improved adverse event rates and a strong trend for improvements in survival. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00121485.This publication has 21 references indexed in Scilit:
- Clinical Strategies and Outcomes in Advanced Heart Failure Patients Older Than 70 Years of Age Receiving the HeartMate II Left Ventricular Assist Device: A Community Hospital ExperienceJournal of the American College of Cardiology, 2011
- Results of the Post-U.S. Food and Drug Administration-Approval Study With a Continuous Flow Left Ventricular Assist Device as a Bridge to Heart Transplantation: A Prospective Study Using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)Journal of the American College of Cardiology, 2011
- Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic CardiomyopathyCirculation: Heart Failure, 2011
- Third INTERMACS Annual Report: The evolution of destination therapy in the United StatesThe Journal of Heart and Lung Transplantation, 2011
- Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure PatientsJournal of the American College of Cardiology, 2010
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceThe New England Journal of Medicine, 2009
- Rise of the Machines — Left Ventricular Assist Devices as Permanent Therapy for Advanced Heart FailureThe New England Journal of Medicine, 2009
- Extended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist DeviceJournal of the American College of Cardiology, 2009
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in AdultsCirculation, 2009
- Use of a Continuous-Flow Device in Patients Awaiting Heart TransplantationThe New England Journal of Medicine, 2007